Core Insights - The article highlights the growing interest of Latin American journalists in China's economic development and modernization, as they explore Guangzhou's historical and contemporary significance [1] Group 1: Economic Development - Latin American journalists express admiration for China's economic growth and technological innovation, viewing it as a potential model for their own countries [1] - The visit to Guangzhou includes insights into the city's historical trade significance during the "Age of Exploration" and its current role in modern commerce and manufacturing [1] Group 2: Cultural Exchange - The visit is part of the "Understanding China" series, aimed at fostering dialogue and understanding between China and Latin America [1] - Journalists from 17 countries participated, indicating a broad interest in learning from China's development experiences [1]

Core Viewpoint - Pacific Bar (08432.HK) has announced a lease agreement for a property in Hong Kong, indicating a strategic expansion in its operations [1] Group 1: Lease Agreement Details - The lease agreement is between Pacific Bar's wholly-owned subsidiary, Pacific Bar (103rd Store) International Limited, and the property owner, Forestar Investment Limited [1] - The fixed lease term is set from December 1, 2025, to November 30, 2028, covering a period of three years [1] - The property in question is located on the sixth floor and rooftop of Zing! at 38 Yau Wa Street, Hong Kong [1]

Group 1 - The company, Jingzhuan Technology, established Jiangsu Pacific Intelligent Joint Co., Ltd. in April 2025 in the humanoid robot sector [2] - In June 2025, the company made an external investment to acquire a stake in Gelanruo Robotics Co., Ltd. [2]

Core Insights - Deep Longevity, Inc is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1] - Deep Longevity aims to establish a local sales team in the U.S. to drive partnerships with various health-related entities [2] Group 1 - Deep Longevity's expansion into the U.S. is a significant milestone, with plans to capture a share of the $6.8 trillion health market [1][2] - The aging clocks developed by Deep Longevity include BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, providing personalized insights for consumers and healthcare providers [1][2] - The company has received support from numerous peer-reviewed papers and patents for its technology, which integrates various biological and psychological factors [2][3] Group 2 - The initial sales focus will be on the Southeastern U.S., including states like Alabama, Florida, and Georgia, with plans to build high-impact partnerships [2] - Deep Longevity's technology offers a vertical software as a service (SaaS) solution that provides personalized recommendations to improve health and extend healthy lifespan [3]

Core Insights - Deep Longevity, Inc. is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1][2] - Deep Longevity aims to establish partnerships with various health-related entities to enhance the distribution of its aging solutions [2] Company Expansion - Deep Longevity is forming a local sales team in the U.S., with the first two sales personnel starting on January 1, 2026 [2] - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2] - The CEO of Deep Longevity emphasized the significance of entering the U.S. market as a milestone for the company [2] Technology and Offerings - The company’s aging clocks integrate various biological markers and psychological factors to provide comprehensive biological aging profiles [2][3] - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, enhancing its credibility in the market [2] - The company offers vertical software-as-a-service (SaaS) solutions that provide personalized recommendations to improve health and extend healthy lifespan [3]

Core Viewpoint - Deep Longevity, Inc. plans to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2]. Group 1: Expansion Plans - Deep Longevity will establish a local sales team in the U.S., with the first two sales personnel joining on January 1, 2026 [2]. - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2]. Group 2: Product Offerings - The company offers clinically validated aging clocks, including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, which provide multi-dimensional biological age assessments beyond chronological age [1][2]. - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, integrating blood biomarkers, epigenetics, psychology, and biology to deliver comprehensive biological aging profiles [2]. Group 3: Business Model - Deep Longevity provides vertical software-as-a-service (SaaS) solutions that offer personalized recommendations to improve health and extend healthy lifespan [3].

二、中国太平洋财产保险股份有限公司浙江分公司应按照有关规定及时办理变更及许可证换领事宜。 2025年11月28日，国家金融监督管理总局衢州监管分局发布批复称，《中国太平洋财产保险股份有限公 司浙江分公司关于变更中国太平洋财产保险股份有限公司江山支公司营业场所的请示》（浙太保产 〔2025〕106号）收悉。经审核，现批复如下： 一、同意中国太平洋财产保险股份有限公司江山支公司的营业场所变更为：浙江省衢州市江山市双塔街 道锦绣大道99幢3号楼503-7室。 ...

Core Viewpoint - The global dry bulk shipping market is experiencing a rapid upturn, with the Baltic Dry Index (BDI) reaching its highest level since December 2023, indicating a positive trend for the industry [1] Group 1: Company Performance - Pacific Basin Shipping (02343) has seen its stock price increase by over 4%, currently trading at HKD 2.71 with a trading volume of HKD 32.43 million [1] Group 2: Industry Outlook - The dry bulk shipping industry is at a turning point, with moderate supply growth and three key demand catalysts expected to drive upward momentum: 1. The commencement of the West Simandou iron ore project, which is set to reshape the iron ore trade landscape 2. The Federal Reserve's interest rate cuts, which are favorable for commodity trading and dry bulk shipping 3. Long-term infrastructure needs, including post-war reconstruction in Ukraine and hydropower projects in Asia, contributing to marginal demand [1]

Core Viewpoint - The global dry bulk shipping market is experiencing a rapid upturn, with significant increases in the Baltic Dry Index (BDI) indicating a positive trend for the industry moving into 2025 [1] Group 1: Company Performance - Pacific Basin Shipping (02343) has seen its stock price rise by over 4%, currently trading at 2.71 HKD with a transaction volume of 32.43 million HKD [1] Group 2: Industry Outlook - The Baltic Dry Index has recorded 12 consecutive increases, reaching 2,560 points as of November 28, marking the highest level since December 2023 [1] - Long-term demand factors are expected to provide upward momentum for the dry bulk shipping industry, including the commencement of the West Simandou iron ore project, potential interest rate cuts by the Federal Reserve, and ongoing infrastructure needs related to post-war reconstruction in Ukraine and hydropower projects [1]

Core Viewpoint - Pacific Securities initiates coverage on Connora-B (02162) with a "Buy" rating and a target price of HKD 82.07, highlighting the rapid growth of the atopic dermatitis drug market in China, driven by core products like Dupilumab and Dupilumab's accelerated market penetration [1] Industry Summary - The atopic dermatitis (AD) drug market in China is expected to grow rapidly, with a compound annual growth rate (CAGR) of approximately 22.6% from 2019 to 2024, and an anticipated CAGR of 18.6% from 2024 to 2030, reaching USD 4.3 billion by 2030 [1] - AD affects up to 20% of children and adolescents and 1-5% of adults globally, with 25% to 30% of patients experiencing moderate to severe symptoms [1] Company Summary - Connora's core product, Dupilumab (Dabizhuo), has become the fourth largest drug globally, with sales in China exceeding CNY 2.5 billion, and projected to grow to over CNY 2.5 billion in 2024, reflecting a growth rate of approximately 33% [1] - The company’s product, Dupilumab (Kangyueda), is in a rapid growth phase, with expected sales of approximately CNY 36 million in 2024 and CNY 170 million in the first half of 2025, driven by increasing medical demand for allergic diseases [2] - CM512, a long-acting TSLP x IL-13 dual antibody developed by Connora, shows promising potential with a half-life of 70 days, allowing for reduced dosing frequency and improved patient compliance [2] Clinical Research Summary - Phase I clinical trials for CM512 in treating adult moderate to severe AD achieved all primary endpoints, with 50% of patients in the 300mg group reaching EASI-75 at week 6, compared to 7% in the placebo group [3] - At week 12, the EASI-75 and EASI-90 response rates for the 300mg dose group were 58.3% and 41.7%, respectively, outperforming existing IL-4Rα monoclonal antibodies and JAK1 inhibitors [3] - Most treatment-emergent adverse events (TEAEs) during the study were mild to moderate, with no reports of serious adverse events leading to treatment delays or study withdrawals [3]